leisure time -WSS

leisure time

author：focus 2025-09-06 04:13:10 - browse：8763

Adobe

LONDON — Merck said Wednesday it is buying ophthalmology-focused startup EyeBio in a deal worth up to $3 billion, as the pharma company looks to diversify its pipeline.

Under the deal, Merck, through a subsidiary, will pay $1.3 billion in cash upfront, with another $1.7 billion potentially included if certain regulatory and commercial milestones are met. The Wall Street Journal first reported the news Tuesday night.

EyeBio has been developing a drug called restoret for a number of retinal diseases, including age-related macular degeneration and diabetic macular edema. It presented data in February from a Phase 1/2 trial of restoret in both conditions. Merck said it plans to move restoret into a pivotal trial for diabetic macular edema later this year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Plastic surgeons increase patient psychiatric screenings

WSS

23andMe had bad news about my health. I wish a person had delivered it

Gene editing the human germline: What are the risks?

State Dept. review finds Biden bears some blame for Afghanistan failures

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Asbestos, a deadly carcinogen, banned by EPA

Trump demands the U.S. pay no more for drugs than other countries … again

knowledge

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

hotspot

Affirmative action in medical school literally saved lives

CVS Caremark has created a new ploy: the drug ‘rebate credit’

State Dept. review finds Biden bears some blame for Afghanistan failures

Activists slam private health insurers over coverage restrictions

Wildfire smoke exposes gaps in outdoor worker protections

Affirmative action in medical school literally saved lives

Virginia high school admissions case could be legal follow

Readout Newsletter: Bluebird, CVS, Contineum

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

SCOTUS questions limit to govt efforts to fight misinformation

knowledge

UnitedHealth increases loan offers after Change Healthcare outage

Future doctors should be trained to promote social change

Nurses recount patients attacks

New air purifier tech could be key to improving indoor air quality

5 to watch: Tech startups trying to solve health care's staffing crisis

BioMarin wins approval for gene therapy to treat hemophilia A

focus

focus

focus

Wikipedia